Burning Rock Biotech Limited (NASDAQ:BNR) Short Interest Update

Burning Rock Biotech Limited (NASDAQ:BNR) was the recipient of a large growth in short interest in July. As of July 15th, there was short interest totalling 41,400 shares, a growth of 5.1% from the June 30th total of 39,400 shares. Based on an average daily volume of 5,900 shares, the short-interest ratio is currently 7.0 days. Currently, 0.5% of the company’s stock are sold short.

Institutional Investors Weigh In On Burning Rock Biotech

A hedge fund recently raised its stake in Burning Rock Biotech stock. Kynam Capital Management LP lifted its position in shares of Burning Rock Biotech Limited (NASDAQ:BNR) by 2.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 8,694,426 shares of the company’s stock after buying an additional 194,426 shares during the period. Burning Rock Biotech comprises 0.9% of Kynam Capital Management LP’s investment portfolio, making the stock its 20th largest position. Kynam Capital Management LP owned 8.47% of Burning Rock Biotech worth $8,086,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 30.03% of the company’s stock.

Burning Rock Biotech Trading Down 4.2 %

Shares of BNR traded down $0.31 on Thursday, reaching $7.05. 287 shares of the company’s stock traded hands, compared to its average volume of 6,033. The stock’s 50 day simple moving average is $6.98 and its two-hundred day simple moving average is $7.67. Burning Rock Biotech has a 52-week low of $5.29 and a 52-week high of $21.00. The stock has a market cap of $72.19 million, a PE ratio of -1.14 and a beta of 0.17.

Burning Rock Biotech (NASDAQ:BNR) last posted its earnings results on Wednesday, May 29th. The company reported ($0.16) earnings per share (EPS) for the quarter. The company had revenue of $17.40 million for the quarter. Burning Rock Biotech had a negative return on equity of 71.22% and a negative net margin of 113.39%.

About Burning Rock Biotech

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.